Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?

  • Don S Dizon
  • Published 2013 in American journal of clinical oncology


Although epithelial ovarian cancer responds well to chemotherapy, patients presenting with advanced disease still have a poor prognosis. The clear role of angiogenesis in the development and progression of ovarian tumorigenesis has led to the development of several novel antiangiogenic agents; however, questions remain as how to best incorporate such agents… (More)
DOI: 10.1097/COC.0b013e318216e699


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics